Technology · Agri-food systems / Food & alt-protein

Human milk oligosaccharides (HMOs)

Precision-fermented human milk oligosaccharides — 2'-fucosyllactose, LNnT and sialylated sugars produced by engineered E. coli or yeast — that feed infant-formula bifidobacteria and block pathogen attachment, now expanding from infant nutrition into adult gut-health supplements.

Risk: medium Food ingredients US · EU · CN Science: why it works → verified 2026-07-05 · 4 Sources (0 independent)

1 · What it gives

Human milk oligosaccharides (HMOs) are complex carbohydrates — the third-largest solid component of breast milk after lactose and lipids — that pass largely undigested through an infant’s upper gastrointestinal tract, instead serving as a selective substrate that feeds beneficial Bifidobacterium infantis and blocks pathogen attachment to the intestinal epithelium. Industrial synthesis is achieved via precision fermentation using genetically engineered non-pathogenic E. coli K-12 strains, along with yeasts such as Saccharomyces cerevisiae and Kluyveromyces lactis. DSM-Firmenich’s Glycom division continued expanding its HMO portfolio into Asia, announcing in March 2026 new regulatory approvals in China, Malaysia and Thailand covering Glycare 3SL 9001 (3’-sialyllactose) and additional 2’-FL/DFL, LNT and 6’-SL sodium salt products for infant nutrition. FrieslandCampina Ingredients secured regulatory approval for its Aequival 2’-FL ingredient in Thailand, extending its use from flavored milk drinks for older children into infant and follow-on formulas. Glycosyn announced in December 2024 the availability for licensing of its commercial high-titer HMO production strains and IP covering prebiotic, anti-inflammatory and anti-infective uses, with strains validated at large fermentation scale for 2’-FL, LNT, 3’-SL and 6’-SL. Novonesis is expanding HMOs beyond infant nutrition into general adult health, targeting immune, metabolic and gut-health applications through gummies, beverages, powders and supplements, backed by an in-house research program spanning in vitro, in vivo, gut-model and human clinical testing.

The key directions of human milk oligosaccharides are:

Fucosyltransferase strain engineering: inserting L-fucosyltransferase genes (typically from Helicobacter pylori or Dictyostelium discoideum) into producer strains to synthesize fucosylated HMOs such as 2’-FL.
Sialyltransferase strain engineering: inserting sialyltransferase genes and optimizing CMP-Neu5Ac (sialic acid donor) synthesis pathways for sialylated HMOs such as 3’-SL and 6’-SL.
Lactose-operon knockout: removing the lacZ, lacY and lacA genes from the producer strain’s genome so the bacterium cannot degrade the lactose acceptor, using it exclusively as a substrate for sugar attachment.
Endotoxin-free downstream purification: multi-stage ultrafiltration, ion-exchange desalting and activated-carbon treatment removing bacterial endotoxins and residual DNA to achieve food-grade purity.

Sectoral value chain#

[Engineered producer strains] ──> [Precision fermentation] ──> [Membrane-based downstream purification]
         │                                  │                                    │
  (E. coli K-12 /                   (Lactose + glucose                   (Filtration, endotoxin
   S. cerevisiae)                    as substrates)                       capture, desalting, carbon)
                                                                                    │
[Infant formula / dietary supplements] <── [Drying & crystallization] <── [Evaporation & concentration]

Value chain levels#

Level	Description	Key inputs/outputs
Strain engineering	Building and optimizing metabolic pathways for sugar-donor synthesis and foreign glycosyltransferase expression in producer cells.	In: Genome editing tools, expression cassettes. Out: Stable HMO-producing engineered strain.
Fermentation	Controlled HMO biosynthesis in aerobic fermenters with continuous feeding of lactose (acceptor) and glucose/glycerol (energy/carbon source).	In: Lactose, glucose, salts, strain inoculum. Out: Fermentation broth containing extracellular HMOs.
Biomass separation	Centrifuging and microfiltering the culture broth to fully remove producer-strain cells before downstream membrane processing.	In: Fermentation broth, centrifuge, microfiltration unit. Out: Cell-free clarified HMO solution.
Downstream purification	Ultrafiltering to remove strain proteins and DNA, demineralizing on ion-exchange resins, decolorizing with activated carbon.	In: Clarified HMO solution. Out: Desalted, purified, endotoxin-free HMO solution.
Crystallization	Vacuum-concentrating the purified solution to supersaturation and selectively crystallizing the target HMO from residual free lactose.	In: Purified HMO concentrate. Out: Ultra-pure crystalline HMO isolate.
Drying and packaging	Spray drying or redissolving/drying the crystalline isolate under sterile conditions, then packaging for B2B distribution.	In: Crystalline HMO isolate, spray dryer. Out: White, high-purity (>95-98%) fine crystalline powder ready for shipment.

Cross-cutting technologies of the sector:

Nucleotide-sugar metabolic engineering: optimizing intracellular GDP-L-fucose synthesis pathways (de novo and salvage) to sustain high lactose-fucosylation rates.
Downstream desalting and ion exchange: multi-stage membrane electrodialysis and ion-exchange chromatography systems fully removing salts, trace nucleic acids and endotoxins from the fermented solution.
Efflux transporter engineering: genetically inserting specific membrane transporters into producer cells to actively export synthesized HMOs from the cytoplasm into the culture medium, eliminating the need for cell lysis.

2 · What it replaces 6 · matched by industry

D1E2	Microalgal omega-3 oils (DHA/EPA) instead of fish oil and krill oil Replaces: Wild-capture fish oil and Antarctic krill oil for omega-3 (food, supplements, infant formula) and part of the aquafeed fish-oil fraction; …	FOOD
D1E–	Fermentation and algal food colours instead of azo dyes (tartrazine, sunset yellow) and titanium dioxide Replaces: Azo food dyes — tartrazine (E102), sunset yellow (E110), azorubine (E122), ponceau 4R (E124), allura red (E129); titanium dioxide (E171) …	FOOD
D3E–	Fermentation-produced chymosin instead of calf rennet in cheesemaking Replaces: Natural calf rennet (abomasum extract from veal calves); part of microbial/mold coagulants where bitterness was the problem	FOOD
D3E–	Fermentation-produced vitamins (B2, B12, C routes) instead of multi-step chemical synthesis Replaces: Chemical vitamin synthesis — Reichstein process for vitamin C (six chemical steps + one fermentation), chemical B2 routes (abandoned), …	FOOD
D3E2	Glutamate and MSG by bacterial fermentation instead of protein hydrolysis and chemical synthesis Replaces: Hydrolysis of wheat gluten or soybean protein with hydrochloric acid (1909–1960s); acrylonitrile-based chemical synthesis (Japan, …	FOOD
D1E–	Baking enzymes (fungal amylase, maltogenic amylase, xylanase, glucose oxidase, lipase) plus ascorbic acid instead of potassium bromate and azodicarbonamide as flour treatment agents Replaces: Potassium bromate (KBrO₃) and azodicarbonamide (ADA) used as oxidizing flour improvers/dough conditioners; part of chemical emulsifier use …	FOOD

3 · How to implement 6 steps

1
Strain metabolic engineeringStrains & cell lines
An E. coli K-12 strain is constructed with the lactase gene (lacZ) removed and an alpha-1,2-fucosyltransferase gene inserted; expression of GDP-L-fucose synthesis enzymes from fructose-6-phosphate (the de novo pathway) is optimized to build an abundant fucose-donor pool in the cytoplasm.
Who can do this step matched automatically
Changjin Bio 昌进生物 (Shanghai) China
✓ FSSC 22000 ✓ ISO 22000
“It specializes in synthetic biology, focusing on the research, development, and industrialization of microbial biomass proteins and recombinant milk proteins.”
Esco Aster Singapore
✓ FSSC 22000 ✓ ISO 22000 5,000 L industrial scale
“Platform and capabilities: end-to-end support from discovery to market approvals, with services spanning cell line creation, GMP/MO handling, CMC/PD/AD, MSAT …”
Amano Enzyme Japan
“Core technology centers on microbial enzyme discovery and production using strain screening (20,000+ strain library), classical mutagenesis/GMO/protein engineering, and …”
2
Aerobic fed-batch fermentationFermentation & cultivation
The process runs in a highly aerated, pressurized fermenter to maximize oxygen supply. Glucose is continuously fed as the energy source; once sufficient biomass concentration is reached, lactose (the acceptor) is introduced into the medium. Bacteria actively transport lactose into the cell, where enzymatic fucose attachment forms 2’-FL, which is exported out of the cell via efflux transporter proteins.
Who can do this step matched automatically
Advanced Enzyme Technologies (NSE) India
✓ FSSC 22000 ✓ ISO 22000 500 m3
“Technology: microbial fermentation with ~500 m3 fermentation capacity; 15+ patents; developed/upscaled probiotic production technologies.”
Changjin Bio 昌进生物 (Shanghai) China
✓ FSSC 22000 ✓ ISO 22000
“With expertise in both biomass fermentation and precision fermentation, Changing Bio produces tasteful and versatile non-GMO mycoproteins, as well as a series of dairy proteins, …”
Esco Aster Singapore
✓ FSSC 22000 ✓ ISO 22000 5,000 L industrial scale
“TideMotion® Bioreactors”
TurtleTree Singapore
industrial scale
“At TurtleTree, we are pioneering the future of health with our breakthrough product, LF+: the world’s first vegan lactoferrin created through cutting-edge precision fermentation …”
ADM / Sophie's BioNutrients Singapore
“Sophie's BioNutrients is a food technology company that produces sustainable, plant-based protein ingredients by fermenting microalgae in bioreactors.”
3
Ultrafiltration (biomass separation)Purification & downstream
The culture broth passes through a centrifuge and microfiltration system for complete bacterial cell separation. The resulting clear solution proceeds to an ultrafiltration cascade (5-10 kDa membranes) removing dissolved proteins, enzymes and residual nucleic acid fragments from the producer strain.
Who can do this step matched automatically
Advanced Enzyme Technologies (NSE) India
✓ FSSC 22000 ✓ ISO 22000 500 m3
“Development of robust, scalable fermentation and downstream processing (production and recovery/yield optimization).”
Esco Aster Singapore
✓ FSSC 22000 ✓ ISO 22000 5,000 L industrial scale
“Adherent cell culture and downstream processing: commercialized Tide Motion bioreactor platform (MiniTide to TideXcell) with closed automated cell harvesting and single-use …”
4
Endotoxin sorption and resin desalting
The sugar solution passes through cation- and anion-exchange resin columns for demineralization, then through a bed of granulated activated carbon that selectively adsorbs pigments, byproduct metabolites and trace lipopolysaccharide endotoxins, achieving crystal-clear solution quality.
5
Selective crystallization of 2'-FLPurification & downstream
The purified 2’-FL solution is concentrated in a multi-effect vacuum evaporator to supersaturation; seed crystals are introduced, and controlled cooling crystallizes ultra-pure 2’-fucosyllactose, separating the target product from residual free lactose in the mother liquor.
Who can do this step matched automatically
Advanced Enzyme Technologies (NSE) India
✓ FSSC 22000 ✓ ISO 22000 500 m3
“Development of robust, scalable fermentation and downstream processing (production and recovery/yield optimization).”
Esco Aster Singapore
✓ FSSC 22000 ✓ ISO 22000 5,000 L industrial scale
“Adherent cell culture and downstream processing: commercialized Tide Motion bioreactor platform (MiniTide to TideXcell) with closed automated cell harvesting and single-use …”
6
Spray drying and big-bag packagingPurification & downstreamField application & services
The crystalline mass is redissolved in deionized water and spray-dried under sterile ISO class D conditions. The dried fine-crystal 2’-FL powder, over 98% purity and under 4% moisture, is packed into sealed B2B kraft bags with polyethylene liners for shipment to infant-formula manufacturers.
Who can do this step matched automatically
Advanced Enzyme Technologies (NSE) India
✓ FSSC 22000 ✓ ISO 22000 500 m3
“Development of robust, scalable fermentation and downstream processing (production and recovery/yield optimization).”
Esco Aster Singapore
✓ FSSC 22000 ✓ ISO 22000 5,000 L industrial scale
“Adherent cell culture and downstream processing: commercialized Tide Motion bioreactor platform (MiniTide to TideXcell) with closed automated cell harvesting and single-use …”

4 · Who delivers

Matched suppliers (matched automatically)

Novonesis	Denmark	Producer	active
dsm-firmenich	Switzerland	Producer	active
TurtleTree	Singapore	Producer	active
Shandong Bailong Chuangyuan (BLD Bio)	China	Research / RTO	active
Perfect Day	United States	Producer	active
Zero Cow Factory	India	Producer	active

In the services and supply catalogue 2 · paid service

Upstream — fermentation & cell culture · Contract manufacturing (CMO/CDMO/toll)

Leading companies and institutes (from the brief)

Company / Institute	Country	Key products / platforms	Tech features	Status 2026
DSM-Firmenich (Glycom)	🇨🇭 Switzerland	Glycare 3SL 9001, 2’-FL/DFL, LNT, 6’-SL	New Asia regulatory approvals (March 2026)	commercial
Novonesis	🇩🇰 Denmark	HMO adult-health formats	Expansion into gummies, beverages, powders (2026)	commercial
FrieslandCampina Ingredients	🇳🇱 Netherlands	Aequival 2’-FL	Thailand infant/follow-on formula approval	commercial
Glycosyn	🇺🇸 USA	Licensable HMO production strains	High-titer 2’-FL/LNT/3’-SL/6’-SL IP (2024)	commercial

5 · Rules & route to market

Route into Russia / EAEU: FOOD · Rospotrebnadzor / EAEU
declaration of conformity, or SGR within 30 calendar days for new/specialized ingredients (plus tests)
Information, not legal advice — confirm the procedure for your product. (2026-10-06)

United States

The United States leads in HMO consumption volume and the depth of clinical research into their effects on infant health as well as adult metabolic stability, cognitive function and gut health.

FDA GRAS approvals, Similac/Enfamil HMO adoption, Glycosyn’s licensing-ready production strains#

FDA GRAS approvals: the US became the first country to approve commercial HMO use, with the FDA issuing GRAS (Generally Recognized as Safe) determinations for 2’-FL, LNnT, 3-FL, LNT, 3’-SL and 6’-SL from leading global producers.
Mass infant-formula adoption: major US infant-formula brands (Similac from Abbott, Enfamil from Reckitt) have fully converted their premium product lines to formulations with mandatory 2’-FL and HMO-blend addition, bringing their protective properties closer to the breastfeeding gold standard.
Glycosyn’s licensing-ready strains: announced in December 2024 the availability for licensing of its commercial high-titer HMO production strains and IP covering prebiotic, anti-inflammatory and anti-infective uses, with strains validated at large fermentation scale for 2’-FL, LNT, 3’-SL and 6’-SL.

European Union

The European Union is the world’s leading R&D hub for HMO research and synthesis, with established scientific and production bases in Denmark and the Netherlands.

DSM-Firmenich’s Asia regulatory expansion, FrieslandCampina’s Aequival approvals, EFSA’s six-HMO blend authorization#

DSM-Firmenich’s Asia regulatory expansion: DSM-Firmenich’s Glycom division continued expanding its HMO portfolio into Asia, announcing in March 2026 new regulatory approvals in China, Malaysia and Thailand covering Glycare 3SL 9001 (3’-sialyllactose) and additional 2’-FL/DFL, LNT and 6’-SL sodium salt products for infant nutrition.
FrieslandCampina’s Aequival approvals: secured regulatory approval for its Aequival 2’-FL ingredient in Thailand, extending its use from flavored milk drinks for older children into infant and follow-on formulas, positioning it as a leading Thai provider offering both HMOs and GOS prebiotics.
EFSA’s six-HMO blend authorization: all new oligosaccharides in the EU undergo the strictest safety-assessment procedure under the Novel Food regulation; for 2025-2026, EFSA approved an expanded blend of six key HMOs (2’-FL, 3-FL, LNT, LNnT, 3’-SL, 6’-SL) for infant and specialized adult nutrition.

China

China is the world’s largest and fastest-growing target market for HMOs, with national health policy directly driving domestic infant-formula fortification standards.

2023 NHC approval milestone, February 2026 3’-SL approval, domestic fermentation foundry buildout#

2023 NHC approval milestone: China’s National Health Commission officially approved 2’-FL and LNnT for use as nutritional fortifiers in infant formula in October 2023, triggering immediate production launches across major Chinese infant-formula brands.
February 2026 3’-SL approval: the NHC took a further regulatory step in February 2026, officially authorizing the sialylated oligosaccharide 3’-sialyllactose for infant nutrition, given sialic acid’s critical role in infant neural connection formation and brain development.
Domestic fermentation foundry buildout: Chinese biotechnology companies are actively developing high-technology domestic foundries for fermentation-based HMO production, having successfully developed and certified proprietary E. coli strains for 2’-FL synthesis to reduce dependence on imported feedstock from Western producers.

6 · Money: tenders & grants

Grant	Continuing Human Enabling Enhancing Restoring and Sustaining Air Force -- Research Lab · United States	Aug 22, 2044 6520 days
Grant	First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based … National Institutes of Health · United States	Oct 15, 2027 364 days
Grant	Health of ecosystems and wild species, predictions and impacts on human health, in the face of existing and … European Commission · EU	Sep 22, 2027 341 days
Grant	African Union – European Union Partnership on Food and Nutrition Security and Sustainable Agriculture (FNSSA) European Commission · EU	Sep 23, 2027 342 days

Public R&D projects 1

Publicly funded research projects (US NSF, and EU, UK and other funders via OpenAIRE) whose title names this technology — matched by title, not reviewed; amounts as awarded, in the funder's currency. all funded projects →

2019

CAREER: Bioorganic Investigation of Human Milk Oligosaccharide Modulation of Group B Streptococcus

NSF · 1847804

1,140,000 USD

7 · Tech stack & innovations

HMO synthesis represents a triumph of metabolic engineering and sophisticated downstream processing:

Genetic pathway construction:
- Fucosylated HMOs (such as 2’-FL) require inserting L-fucosyltransferase genes (typically from Helicobacter pylori or Dictyostelium discoideum) into the host cell (E. coli); sialylated HMOs (3’-SL, 6’-SL) require sialyltransferase genes and optimized CMP-Neu5Ac donor synthesis pathways; blocking degradation requires fully removing the lactose-operon genes (lacZ, lacY, lacA) so the producer strain uses incoming lactose exclusively as an acceptor substrate rather than degrading it.
Advanced downstream purification:
- Bacterial synthesis in E. coli carries endotoxin (cell-wall lipopolysaccharide) contamination risk; achieving food safety requires multiple rounds of nanoporous membrane filtration (under 1 kDa pore size, ultrafiltration) and sorption on specialized activated carbons with controlled pore distribution, guaranteeing complete absence of endotoxins and strain DNA traces.

Sources 4 · 0 independent · 4 producer sites

Producers' own sites 4

Dsm firmenich producer checked 2026-03-05 · link not kept
Frieslandcampina ingredients producer checked 2026-06-23 · link not kept
Glycosyn producer checked 2026-05-14 · link not kept
Novonesis producer checked 2026-01-22 · link not kept